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ABSTRACT
Pyrrolobenzodiazepines (PBDs) are a group of naturally occurring compounds that were
discovered in the cultures of Streptomyces in the 1960s. Some natural PBDs discovered in these
cultures, such as anthramycin and sibiromycin, were shown to possess a broad spectrum of antitumor activity. Since cancer is still a leading cause of death globally, the development of novel
anti-proliferative derivatives of PBDs is essential for human welfare worldwide. Further
synthesis and structure-activity relationship (SAR) studies of the parent natural products and
their tetracyclic analogs will lead to the discovery of drug candidates. In this work, thirteen PBD
analogues were synthesized using no more than three to four synthetic steps, beginning with
commercially obtainable L-proline and isatoic anhydride. The MTT assay, which is a
colorimetric assay that uses 3-(4,5-Dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide
(MTT) to assess cell metabolic activity, was initially implimented to test the in vitro cytotoxicity
of the compounds using multiple cell lines, namely: SKBR-3, MCF-7, SKMEL-2, CaCo 2, HCT
116, and Mia Paca. Nearly all of the compounds decreased the cell viability of MCF-7 by
roughly 20%. Additionally, the anti-proliferative activity of the PBD products were further
evaluated by the NCI-60 Human Tumor Cell Lines Screen, which is a part of the National
Cancer Institute’s Development Therapeutics Program - Drug Synthesis and Chemistry Branch.
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CHAPTER 1
INTRODUCTION
Cancer is one of the most formidable opponents of modern healthcare. It is projected by
the American Cancer Society that 39.6% of men and women will develop cancer at some point
in their life time.1 In addition, the Centers for Disease Control states that cancer is the second
leading cause of death in the United States, not far behind heart disease (Figure 1).2 Even when
cancer is diagnosed early, the most modern treatments fail to completely cure the patient at
times.

Figure 1: Leading causes of death of both men and women in 2014 as reported by the CDC.2

Cancer is a difficult disease to treat because cancers originating in different tissues
respond differently to certain treatments; in addition, cancers that developed in the same tissue,
but occur in different people, will respond to treatments differently. Therefore, to combine all of
these diseases under one name, being “cancer”, can often be misleading by oversimplifying the
disease; instead, it’s better to look at the different types of cancer, which are categorized by the
9

tissue in which they originated in, as a multitude of diseases with one common feature:
uncontrolled cell division.3
There are three classical modes of cancer treatment: surgical removal, electromagnetic
radiation therapy, and chemotherapy. These discrete modes of treatment all have their pros and
cons individually; however, they are most often used together in a treatment regimen to have the
most efficacious result. Surgical removal was the first method developed to treat tumors, and is
often the first choice today; however, not all tumors are accessible by the surgeon, and often the
tumors that are removed will grow back over time. Electromagnetic radiation therapy, which was
the second method invented for cancer treatment, uses electromagnetic radiation to dismember
the DNA of cancer cells, eventually causing cell death; unfortunately, electromagnetic radiation
has been shown to cause cancer in healthy tissues as well. Therefore, it is critical that physicians
applying this form of treatment are able to target only the cancerous cells directly.
Arguably one of the most pivotal moments for the treatment of cancer was the advent of
chemotherapy. Chemotherapy was the first cancer treatment to completely cure metastatic
cancer.4 Chemotherapeutic agents work by interrupting the cell cycle of cells that are actively
reproducing. Different chemotherapeutic drugs target cells at different stages of the cell cycle;
understanding the mechanisms by which individual chemotherapeutic drugs work helps
oncologists to predict which drug combinations would be the most effective.5 There are a
number of different classes of chemotherapeutic drugs that are divided based upon characteristics
such as the mechanisms by which they inhibit cancer cell growth, their chemical structure, and
their relationship to other drugs. One such group of chemotherapeutic drugs is alkylating agents,
which directly damages the DNA of a cell to keep it from reproducing; these drugs may damage
the DNA in all phases of the cell cycle, and are used to treat many different forms of cancer.6
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Pyrrolobenzodiazepines
Pyrrolobenzodiazepines (PBDs) are a group of naturally occurring compounds that were
first discovered in the cultures of Streptomyces. The first PBD molecule to be isolated and
characterized was anthramycin; since then, a number of naturally occurring PBDs have been
isolated from Streptomyces, which include sibiromycin and tomaymycin, among others.7 Similar
to other naturally occurring antibiotics used in medicine, PBDs were developed by Streptomyces
as a means of chemical defense against invading microorganisms; however, scientists have been
able to use their antibiotic properties for the treatment of cancer.
To date, thirteen natural PBD structures have been isolated from Streptomyces including,
but not limited to, anthramycin, tomaymycin, sibiromycin, chicamycin A, and DC-81 (Figure
2).8 Of the thirteen PBD products that have been isolated, both anthramycin and sibiromycin
were shown to have broad spectrum antitumor activity against transplanted tumors.7 As a result,
these natural products were tested clinically. Anthramycin particularly was found to have
significant cytotoxicity against a number of types of cancer, including gastrointestinal, breast
cancers, lymphomas and sarcomas without having significantly ill effects towards red blood
cells. However, like other antitumor antibiotics, the clinical use of anthramycin has been limited
due to its inherent dose-limiting cardiotoxicity.9
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Figure 2: Naturally occurring PBDs that have been isolated from the cultures of Streptomyces.8

Pyrrolobenzodiazepines are characterized by their reoccurring tricyclic structure, which is
composed of an aromatic A-ring, a 1-4-diazepin-5-one B-ring, and a pyrrolidine C-ring (Figure
3). The PBD compounds differ from one another by the location and type of substituent groups
on all three rings; however, in every case, carbon C11 is electrophilic.10 Additionally, the C11a
carbon has an S-configuration, which gives the molecules a right-handed twist when viewed
from the C-ring towards the A-ring.
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Figure 3: The core structure of PBDs; naturally occurring cytotoxic PBDs.
When considering the interaction between PBDs and DNA, the study of DNA’s helical
structure is vital. Double-helical B-DNA is composed of two alternating parts: the major and
minor groove.10 The major groove is wider and deeper in comparison to the minor groove,
making it more accessible to interacting molecules; in contrast, the minor groove is more shallow
and narrow, causing its accessibility to be more selective. Additionally, the major grooves
contain the methyl group of thymine which assists the association of the major groove with
proteins. Each groove contains very specific base pair arrangements, with each base containing
hydrogen bond donors and acceptors. The differences between the donor and acceptor groups of
the base pairs, in addition to the size and spacing of the major and minor grooves, opens up the
possibility of selectivity for drugs.
Pyrrolobenzodiazepines are cytotoxic compounds that behave as alkylating agents,
forming covalent bonds with DNA. As noted previously, alkylating agents may damage DNA at
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any stage of the cell cycle, and are used to treat many forms of cancer. Pyrrolobenzodiazepines
exhibit an electrophilic carbon atom at the C11 position, which allows the PBDs to alkylate the
nucleophilic -NH2 group of guanine bases in the minor groove of DNA, forming an aminal bond
(Scheme 1).11 The covalent bonds that the PBDs form to the amino group of the guanine base
allows the molecules to act as an adduct that blocks biological processes such as transcription
and RNA polymerase progression.12
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Scheme 1: Proposed mechanism of aminal bond formation between PBD and N2 of guanine.11

As noted before, PBDs have an S-configuration at carbon C11a which gives the
molecules a right-handed twist. This right-handed twist differentiates PBDs from other families
of DNA-alkylating agents in that it gives the PBDs the ideal three-dimensional shape which
allows them to fit snugly within the DNA double helix, enabling them to interact with the minor
groove. The ability of PBDs to interact with the minor groove of DNA is essential. In fact, a
synthetic PBD with R-configuration at C11a was shown to lack DNA binding affinity and in
vitro cytotoxicity.13 The minor groove is vulnerable precisely because it is normally unoccupied,
due to the fact that the majority of DNA interacting molecules, such as proteins, only interact
with the major groove.
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After the detection and elucidation of anthramycin’s structure in 1965, its first total
synthesis was reported three years later. Since the discoveries of natural PBDs that have a
significant amount of cytotoxicity, chemists have synthesized many analogues with hopes of
discovering new lead compounds with potent anti-proliferative activities and specific sequence
recognition. [10,11] The goal of these syntheses is to introduce new substituents to the basic
structure, and to ultimately enhance the cytotoxicity of the PBD molecules. An example of the
synthesis of the basic structure of a PBD is shown below as Scheme 2:
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Scheme 2: An example of a synthetic route of the synthesis of the core PBD structure.14

All natural PBDs that have been isolated from Streptomyces cultures are classified today
as PBD monomers. Their classification as monomers is not strictly due to their existence in
nature, but rather that all of the natural PBDs separated from Streptomyces cultures contain only
one unit of the core PBD structure per molecule. Naturally, focus on the synthesis and
enhancement of PBD monomers came first due to their reoccurring existence in the cell cultures
of Streptomyces. Among the natural products, the PBDs which contained endo-exo unsaturation
at the C2 position are the most potent; additionally, research has shown that PBD monomers
produced synthetically that contain C2-unsaturation (C-ring) have enhanced in vitro potency.15
More than 80 C2-aryl-substituents have been synthesized, with carbocyclic and heterocyclic C2aryl substituents ranging from single aryl rings to fused rings systems, which has established the
molecular requirements of the C-ring for in vitro cytotoxicity.11 Due to the success of these
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structures in vitro, two of them were tested in vivo, namely SG2738 and SG2042. SG2738 was
tested on a HCT-116 human colon xenograft, but only produced a modest delay in the colon
tumor growth; SG2042 was tested in six human tumor xenografts, with some antitumor activity
in renal models and breast cancer models.11,16 The structures of SG2738 and DRH417/SG2042
are shown below (Figure 4):
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Figure 4: The structures of two cytotoxic synthetic PBD monomers, SG2738 and
DRH417/SG2042.

The second class of the synthetic PBDs are PBD dimers. These synthetic molecules are
named dimers because they contain two complete units of the core PBD structure (two
monomers). The concept behind synthesizing PBD dimers was to generate molecules which
contained the PBD antitumor characteristics, but also to span greater length of DNA; with the
increased length of the molecules and the active constituents of the core PBD structure on both
ends, the dimers were predicted to form cross-links between the DNA strands. Cross-links such
as those proposed to be formed by PBD dimers have the ability to seal the interweaving strands
of DNA together, thus preventing the process of replication and ultimately cell growth. DNA
cross-linking agents such platinum drugs and nitrogen mustards are widely used in modern
chemotherapeutic regimens.17
Near the end of the 20th century, a PBD dimer known as DSB-120 was formed by linking
two DC-81 monomer PBDs through their aromatic A-ring phenol C8-positions.10 In comparison
16

to its PBD monomer DC-81, the dimer revealed an increased DNA binding affinity. The dimers
improvement in biological activity has been attributed to its irreversible interstrand cross-linking
ability on DNA due to the presence of its two active sites. DSB-120 was shown to be highly
cytotoxic in vitro; however, the potential drug’s in vivo studies were not promising.17 The
structure of DSB-120 is shown below (Figure 5):
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Figure 5: The structure of DSB-120, a PBD dimer which showed enhanced DNA binding
affinity as compared to its monomer analogue.

Due to the success of DSB-120 in vitro, a second category of PBD dimers were
synthesized, being modeled after the structure of the natural product tomaymycin, which
contains unsaturation at the C2 position. As previously noted, all of the natural products that
contain unsaturation at the C2 position were shown to have the highest amount of cytotoxicity in
vitro. Due to the efforts to synthesize PBDs which shared the characteristics of the relatively
successful natural PBD products, a dimer by the name of SJG-136 was synthesized and was
shown to be significantly more cytotoxic than DSB-120, in vitro (Figure 6).18 As with DSB-120,
the increased cytotoxicity of SJG-136 is attributed to its enhanced ability to form DNA
crosslinks due two active sites. As a result of impressive in vitro studies, SJG-136 was tested
thoroughly in vivo against 10 human tumor xenografts, including melanomas, breast cancer,
colon cancer, and lung cancer. The SJG-136 compound shown to be active (tumor mass
reduction) against all 10 models.19
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Figure 6: The structure of the highly successful PBD SJG 136.7

Due to the impressive and extensive data collected regarding SJG-136’s activity both in
vitro and in vivo, the potential drug entered clinical Phase I testing against advanced solid tumors
in 2004.7 During Phase I of the clinical trials, different dosing schedules were tested to determine
the best mode of dosing for the drugs. During the most effective dosing schedule, SJG-136 had
promising results. For instance, a patient with malignant melanoma achieved stable disease while
being treated with SJG-136; also, a patient with leiomyosarcoma had stable disease for 18
weeks.7 In addition, a patient with ovarian carcinoma achieved a 62% decrease in tumor size,
lasting for eight months. Due to the success of SJG-136 during Phase I clinical trials, the
compound has recently progressed to Phase II.
The success of the particular PBD dimer SJG-136, currently in Phase II clinical trials, has
once again ignited interest in developing new PBDs. However, the syntheses of PBD dimers are
generally lengthier and more difficult than the syntheses of PBD monomers, which has limited
the scope of structural diversification of the dimers.11 Therefore, there has been an increasing
interest in progressing PBD monomers to clinical trials. There are still structural areas of the
PBD monomers left uncovered by scientists. Most research as gone into the development and
characterization of different substituents on the C-ring of the monomers. However, there is still
much research to be done on the relationship between chemical substituents and cytotoxic
activity in regards to both the A and B rings.
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CHAPTER 2
EXPERIMENTAL
Materials & Methods
All reactions proceeded from the commercially available L-proline and isatoic anhydride.
Unless otherwise stated, all reagents and solvents were obtained from commercial vendors and
utilized without further purification. 1H-NMR, 13C-NMR, GC-MS and IR spectroscopy were the
techniques used for the characterization of the synthesized compounds. A JEOL-NMR Eclipse400 MHz spectrophotometer provided all NMR data and spectra. The high frequency position
conversion gave the different chemical shifts of all peaks in parts per million (ppm) with the
coupling constants value (J) reported in Hz. The splitting patterns of resonance were also
described as follows: singlet (s), doublet (d), doublet of doublet (dd), doublet of doublet of
doublet (ddd), triplet (t), quartet (q), and multiplet (m). A Mattson Genesis II FT-IR spectrometer
was also used for all IR spectra. Cambridge Melt-Temp device provided melting point readings,
but without correction for the synthesized compounds. A Shimadzu GC-MS 2010 System
provided the relative abundances of the smaller ion fragments from the molecular ion of all
compounds. Other common chromatographic techniques such as thin layer chromatography and
column chromatography were also employed in the purification of all synthesized compounds.
Compounds 5 and 6 were synthesized according to previously reported methods.30c
Experimental Procedures
(S)-1,2,3,11a-tetrahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-5,11(10H)-dione (1)
Dilactam (1) was synthesized according to the previously reported methods with some
modifications.14 A suspension of isotaic anhydride (10.0 g, 61.34 mmol) and L-proline (7.06 g,
61.34 mmol) in N,N-dimethylformamide (DMF) (50 mL) was heated to 155 ˚C for 5 h. After
cooling to room temperature, the solvent was removed in vacuo and the residue was taken up in
19

water. The precipitate was collected and dried to give an off-white solid. Recrystallization from
acetone/DMF (10:1 v/v) afforded 10.87 g (82%) of pure Compound 1 as off-white crystals.
Yield: 82.0%; m.p: 223-225 oC; ; [𝜶]

𝟐𝟓
𝑫

= + 512o (c 0.5, MeOH); 1H-NMR (400 MHz, DMSO-

d6): δ = 1.80 (d, J = 9.9 Hz, 1H), 1.85-2.07 (m, 2H), 3.39-3.52 (m, 1H), 3.51-3.67 (m, 1H), 4.024.21 (m, 1H), 7.07-7.17 (m, 1H), 7.17-7.27 (m, 1H), 7.51 (ddd, J = 8.6, 6.8, 1.3 Hz, 1H), 7.78
(dd, J = 7.9, 1.6 Hz, 1H), 10.52 (s, 1H); 13C-NMR (100 MHz, DMSO-d6): δ = 23.6 (C-2), 26.3
(C-1), 47.4 (C-3), 56.8 (C-11a), 121.8, 124.4, 127.1, 130.8, 132.6, 136.9, 165.0 (CO), 171.3
(CO); IR (KBr); 3222 (N-H), 3206, 2955, 2918, 2850, 1691 (C=O), 1680 (C=O), 1621, 1551,
1536, 1479, 1443, 1412, 1385, 1285, 1259, 1179, 759, 701, 615; GC-MS (70 eV) m/z (%): 216
(10) [M+], 119 (14), 92 (20), 70 (100), 64 (10).

(S)-11-thioxo-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one (2)
A mixture of Compound 1 (21.60 g, 100 mmol) and Lawesson’s reagent (20.2 g, 50
mmol) in THF (400 mL) was stirred over night at room temperature. Evaporation of solvent in
vacuo gave a crude solid yellow residue. The solid was washed with toluene and further washed
with cold toluene to afford 20.2 g (87%) of pure Compound 2 as yellow solid.14,23 Yield: 87.0%;
25

m.p.: 272274 oC ; [𝛼]

𝐷

= + 762 o (c 0.5, CHCl3); 1H-NMR (400 MHz, DMSO-d6): δ =

1.831.98 (m, 1H), 1.982.15 (m, 2H), 2.88 (d, J = 5.9 Hz, 1H), 3.313.51 (m, 3H), 3.533.60
(m, 1H), 4.28 (d, J = 6.2 Hz, 1H), 7.29 (d, J = 8.1 Hz, 1H), 7.327.39 (m, 1H), 7.58 (td, J = 7.7,
1.2 Hz, 1H), 7.83 (dd, J = 7.7, 1.5 Hz, 1H); 13C-NMR (100 MHz, DMSO-d6): δ = 23.2 (C-2),
29.5 (C-1), 47.4 (C-3), 60.3 (C-11a), 122.3, 126.2, 128.3, 130.8, 132.7, 137.0, 164.7 (CO), 202.5
(CS); IR (KBr): 3125 (N-H), 3094, 3063, 3024, 2974, 1620 (C=O), 1579, 1523, 1478, 1452,
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1418, 1381, 1272, 1193, 1166, 1145, 1103, 1069, 1055, 887, 833, 817, 786, 755, 695, 664, 625;
GC-MS (70 eV) m/z (%): 232 (7) [M+], 108 (6), 70 (100), 68 (6).
(S,E)-11-hydrazono-1,2,3,10,11,11a-hexahydro-5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-5-one
(7)
A solution of Compound 2 (1.16 g, 5.0 mmol) in ethanol (20 mL) was added 98%
hydrazine monohydrate (0.75 g, 15.0 mmol) and stirred for 15 h at room temperature. The
solvent was removed in vacuo and the residue was taken up in water. The precipitate was
collected, dried and washed with diethyl ether to afford 1.14 g (99%) of Compound 7 as off𝟐𝟓

white solid.27 Yield: 99.0%; m.p: 178180 oC; [𝜶]

𝑫

= + 552 o (c 0.5, MeOH); 1H-NMR (400

MHz, CDCl3): δ = 1.612.08 (m, 4H), 2.652.82 (m, 1H), 3.573.69 (m, 1H), 3.713.84 (m,
1H), 4.174.30 (m, 1H), 6.85 (d, J = 8.1 Hz, 1H), 7.09 (t, J = 7.7 Hz, 1H), 7.327.40 (m, 1H),
7.90 (dd, J = 7.9, 1.3 Hz, 1H); 13C-NMR (100 MHz, CDCl3): δ = 23.4 (C-2), 26.1 (C-1), 47.3 (C3), 55.5 (C-11a), 119.7, 123.0, 125.4, 131.5, 132.5, 137.8, 152.2, 166.2 (CO); IR (KBr): 3484,
3282, 3240, 3161, 2967, 2949,2871, 2814, 2422, 2358, 2336, 1957, 1854, 1784, 1766, 1726,
1689, 1658, 1619, 1563, 1539, 1529, 1479, 1442, 1384, 1323, 1272, 1202, 1076, 943, 903, 825.

(S)-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4-c][1,4]diazepine3,9(2H)-dione (8)
A solution of Compound 7 (0.69 g, 3.0 mmol) and 1,1-carbonyldiimidazole (3.89 g, 24.0
mmol) in dioxane (25 mL) was refluxed for 24 hours. The solvent was removed in vacuo and the
crude product was purified by flash gel column chromatography using gradient elution. The
ratios of solvent mixture used were EtOAc/Hexane (1:1, 2:1, 4:1 v/v) and a final elution with
only Ethyl acetate (EtOAc). Recrystallization from EtOAc/Hexane (4:1 v/v) afforded 0.76 g
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𝟐𝟓

(99%) of pure Compound 8 as white crystals. Yield: 99.0%; m.p: 238240 oC; [𝜶]

𝑫

= + 136 o (c

= 0.5, DMSO); 1H-NMR (400 MHz, CDCl3): δ = 1.992.22 (m, 2H), 2.232.37 (m, 1H), 2.86
(ddd, J = 16.3, 6.8, 3.7 Hz, 1H), 3.643.75 (m, 1H), 3.813.92 (m, 1H), 4.53 (dd, J = 8.4, 3.3
Hz, 1H), 7.427.51 (m, 1H), 7.597.67 (m, 1H), 7.907.98 (m, 1H), 8.03 (dd, J = 7.9, 1.6 Hz,
1H), 9.90 (s, 1H); 13C-NMR (100 MHz, CDCl3): δ = 23.5 (C-2), 26.0 (C-1), 47.7 (C-3), 51.7 (C11a), 123.0, 127.8, 129.0, 130.1, 131.9, 132.3, 153.9 (CO), 164.7 (CO); IR (KBr): 3435, 3375,
3183, 3091, 3000, 2909, 2878, 2814, 2326, 1711, 1611, 1574, 1490, 1466, 1412, 1343, 1285,
1239, 1202, 1167, 1118, 1072, 1024, 979, 926, 912, 825, 786, 758, 709, 656, 616; GC-MS (70
eV) m/z (%): 256 (60) [M+], 102 (26), 90 (38), 43 (100).

(13aS)-3-mercapto-11,12,13,13a-tetrahydro-9H-benzo[e]pyrrolo[1,2-a][1,2,4]triazolo[3,4 c][1,4]diazepin-9-one (9)
A solution of Compound 7 (0.23 g, 1.0 mmol) and 1,1-thiocarbonyldiimidazole (1.42 g,
8.0 mmol) in dioxane (20 mL) was refluxed for 24 h. The solvent was removed in vacuo and the
crude product was purified by flash gel column chromatography using gradient elution. The
ratios of solvent mixture used were Acetone/Hexane (10:1, 20:1 v/v). Recrystallization from
EtOAc/Hexane (4:1 v/v) afforded 0.217 g (80%) of pure Compound 9 as brown crystals. Yield:
80.0%; m.p: >230 oC (dec.); [𝛼]
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𝐷

= + 37.5 o (c 0.4, CHCl3); 1H-NMR (400 MHz, CDCl3): δ =

1.621.99 (m, 1H), 2.032.28 (m, 2H), 2.292.45 (m, 1H), 2.89 (tt, J = 9.9, 3.4 Hz, 1H),
3.633.78 (m, 1H), 3.813.97 (m, 1H), 4.55 (dd, J = 8.4, 2.9 Hz, 1H), 7.507.60 (m, 1H),
7.637.77 (m, 1H), 8.04 (dd, J = 7.7, 1.5 Hz, 1H), 8.39 (d, J = 8.1 Hz, 1H); 13C-NMR (100
MHz, DMSO-d6): δ = 23.6 (C-2), 26.7 (C-1), 47.5 (C-3), 51.6 (C-11a), 126.2, 129.1, 130.6,
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130.8, 131.2, 131.4, 153.1, 164.0 (CO), 167.7 (CS); IR (KBr): 3735, 3280, 3174, 3127, 3096,
3060, 2989, 2944, 2880, 2827, 2415, 2359, 2331, 1958, 1760, 1723, 1686, 1611, 1542, 1488,
1410, 1344, 1310, 1286, 1216, 1112, 1043, 1003, 973, 921, 892, 876, 825, 756, 704, 664, 638,
622, 610; GC-MS (70 eV) m/z (%): 272 (100) [M+], 116 (23), 90 (34), 70 (33).

5,6-Dihydro-4H-3-thia-6a,11b-diazabenzo[g]cyclopenta[e]azulene-1,7-dione (13)
To a solution of Compound 2 (0.464 g, 2.0 mmol) in anhydrous THF (40 mL) was added
freshly distilled α-bromoacetyl chloride (0.39 g, 2.4 mmol). The mixture was stirred for 15 h at
room temperature under nitrogen and then quenched by addition of saturated sodium bicarbonate
(NaHCO3) (20 mL). After extraction with chloroform (2 × 20 mL), the combined organic layers
were dried over Na2SO4, and the solvent was removed under reduced pressure. The crude residue
was subjected to flash silica gel column chromatography using EtOAc/Hexane (4:1 v/v) as eluent
and the solvent was evaporated under reduced pressure to give crude yellow solids.14 The crude
solid was purified by recrystallization from Ethanol/Water mixture to afford 0.20 g (75%) of
pure Compound 13 as yellow needle-like crystals. Yield: 75.0%; m.p: 165167 oC; 1H-NMR
(400 MHz, CDCl3): δ = 1.982.05 (m, 2H), 2.67 (t, J = 8.0 Hz, 2H), 3.83 (s, 2H,), 3.903.94 (m,
2H,), 7.287.32 (m, 1H), 7.44 (dd, J = 8.2, 1.0 Hz, 1H), 7.517.55 (m, 1H), 8.00 (dd, J = 8.0,
1.6 Hz, 1H); 13C-NMR (100 MHz, CDCl3): δ = 20.8 (C-5), 31.1 (C-4), 35.8 (C-2), 50.1 (C-6),
115.5, 124.3, 124.9, 127.2, 128.5, 133.3, 133.6, 138.9, 165.4 (CO), 172.7 (CO); IR (KBr): 3398,
3357, 3282, 2944, 2880, 2790, 2419, 2385, 2350, 2323, 1856, 1818, 1779, 1724, 1690, 1582,
1482, 1404, 1384, 1358, 1334, 1217, 1126, 1092, 871, 835, 776, 708, 659, 636.
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X-ray Crystallography
A large colorless prism was cut (0.10 x 0.15 x 0.23 mm3) and centered on the goniometer
of a Rigaku Oxford Diffraction Gemini E diffractometer operating with MoK radiation. The
data collection routine, unit cell refinement, and data processing were carried out with the
program CrysAlisPro25. The Laue symmetry and systematic absences were consistent with the
monoclinic space groups I2 and I2/m. As the sample was known to be enantiomerically pure, the
acentric space group, I2, was chosen to give Z=4 and Z’=1. The absolute configuration could not
be determined because of anomalous dispersion effects. The structure was solved using
SHELXS-201426 and refined using SHELXL-201426 via Olex227. The final refinement model
involved anisotropic displacement parameters for non-hydrogen atoms and a riding model for all
hydrogen atoms.
Cell Culture Maintenance
The cells lines that originated in multiple tissue types were obtained were obtained from
the American Tissue Type Culture Collection (ATCC), including: breast (SK-BR-3, MCF-7),
colon (Caco-2, HCT 116), melanoma (SKMEL-2), and pancreatic (Mia Paca) cell lines. The
tumor cell lines were grown in their respective medium according to ATCC instructions. Each
medium was supplemented with 10% serum and penicillin/streptomycin. Cell lines were allowed
to reach 75% confluency before treatment with the novel pyrrolobenzodiazepines or negative
control (DMSO at a final maximum concentration of 0.01%).
The cell lines obtained from the ATCC were stored in liquid nitrogen until ready to use.
Once the compounds were synthesized and ready to be tested, each cell line was allowed to thaw
at room temperature, respectively. They were then transferred to a centrifuge tube, diluted by 5
mL of their respective media (listed on the ATTC website), and centrifuged for 3 minutes. The
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supernatant fluid was then removed, and the pellet was re-suspended in 10 mL of its media, and
mixed thoroughly using a pipette. Finally, the solution was transferred to a 25-cm2 vented flask,
and placed in an incubator. The incubator maintained an atmosphere of 37 oC and 5% carbon
dioxide.
The media inside the culture flask was exchanged with fresh media every few days in
order to remove dead cells and provide fresh nutrients. The cells were allowed to grow until they
reached 75% confluency. Once cells were 75% confluent, the media was removed from the flask
and 1.5 mL of trypsin was added in order to lift the cells from the flask. The solution of cells was
then transferred to a centrifuge tube, and diluted with 5 mL of media. Again, the solution was
centrifuged for 3 minutes until all of the cells formed a pellet in the bottom of the tube. The
supernatant fluid was then removed and replaced with 10 mL of media, and the pellet was mixed
well into solution.
MTT Assay
The first method used to test the in vitro cytotoxicity of our compounds was the MTT
Assay. For our tests, we used 48-well plates. 1 mL of each cell line’s respective media was
placed into each well of the 48-well plates, and 1 drop of the final solution of the cells listed in
the previous section were be added to each well and allowed to grow to 75 % confluency
(covering 75% of the bottom of the well). Next, our products were added to the wells at a
concentration of 100 µM, except for four wells in which DMSO was added so that the final
concentration was 0.01% (negative control). Once the PBD products were added in triplicate, the
plates were incubated for 48 hours.
After 48 hours of incubation, 5-diphenyl-tetrazolium bromide (MTT) was added at 100
µg/well and will be incubated for 3-4 hours. After 3-4 hours of incubation, the supernatant fluid
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was removed and 0.1 M HCl in isopropanol was added to each well to dissolve the resulting
formazan crystals. The crystals were dissolved into solution well using a transfer pipette. The
optical density of the resulting solution was measured at 570 nm. The optical density of the
solution of the formazan crystals is directly correlated to the remaining number of viable cells in
solution. Percent cell viability was calculated by comparing the concentration of formazan
crystals formed in the negative control to the formazan crystals formed by the sample in which
our PBD products are added. The cell viabilities of the negative controls were taken to be 100%.
NCI-60 Human Tumor Cell Lines Screen
NCI-60 Human Tumor Cell Lines Screen is a part of the National Cancer Institute’s
(NCI) Development Therapeutics Program (DTP)-Drug Synthesis and Chemistry Branch. The
screening utilizes 60 different human tumor cell lines to identify and characterize novel
compounds with growth inhibition or cell death. The 60 human tumor cell lines represent
leukemia, melanoma, and cancers of the lung, colon, brain, ovary, breast, prostate, and kidneys.
The NCI-60 screening is free of cost to those who submit compounds; however, compounds
submitted are reviewed and only those that meet the guidelines set by the NCI are selected for
screening.
Compounds that selected for the NCI-60 cell screening are initially dissolved in
DMSO:glycerol 9:1 and tested at a single concentration of 10 µM. The One-dose data is reported
in graphical form as a mean of the percent growth of treated cells (Figure 7). The value reported
for the One-dose assay of the individual compounds is cell growth relative to the no-drug control
in addition to the initial number of tumor cells present, which allows for the detection of both
growth inhibition (values between 0 and 100) and tumor cell death (values less than 0).
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Compounds that satisfy predetermined thresholds for the One-dose assay set by the NCI are
tested by a Five-dose assay.

Figure 7: The NCI-60 Human Tumor Cell Lines Screen for 8.
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CHAPTER 3
RESULTS AND DISCUSSION
Chemistry
Syntheses of Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) Derivatives
The synthesis of all PBD derivatives were accomplished with the readily available core
structure of the PBDs (1) using L-proline and isatoic anhydride (from Isatis indigotica20) as the
starting materials. As depicted in the synthesis plan (Scheme 3), the cyclocondensation of an
equimolar mixture of L-proline and isatoic anhydride in DMF at 155 oC by a standard
protocol14,21,22 afforded Compound 1. The product of this reaction was then recrystallized from a
10:1 v/v mixture of acetone and DMF to obtain an 82% yield of Compound 1 as off white
crystals. Thionation of Compound 1 with 0.5 equiv Lawesson’s reagent in THF at room
temperature also afforded Compound 2 in 87% yield.23
Our attempts to synthesize the tetracyclic PBD analogs 3-13 from Compound 2 as shown
in Scheme 3 was highly successful. Catalytic amination of Compound 2 using n-propylamine in
the presence of mercury (II) chloride as catalyst afforded Compound 3 in an 88% yield after
being recrystallized from nitromethane. The cyclization of Compound 3 with bis (2,4,6trichlorophenyl)-2-phenylmalonate at 190 oC using a zincke apparatus to afford the pyrimidineannulated Compound 4 in 75% yield by a neat reaction approach. Cyclization reactions of N,N’disubstituted amidines with bis (2,4,6-trichlorophenyl)-2-phenylmalonates have generally been
shown to result in the formation of pyridinium-4-olates. One possible mechanistic explanation
for the synthesis of these compounds is the loss of two molecules of trichlorophenol through a
ketene intermediate during ring closure.14
A standard protocol was followed for the treatment of Compound 2 with hydrazine
monohydrate in ethanol at room temperature14 to afford Compound 7 in a quantitative yield (i.e.
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99%) which was further used as the main precursor for the syntheses of tetracyclic triazole PBD
(8) and mercapto triazole PBD (9). Carbonylation of 7 with 1,1’-carbonyldiimidazole (CDI) in
dioxane under reflux resulted in the formation of Compound 8 and upon further purification by
flash gel column chromatography, pure 8 was afforded as white crystals in 99% yield. The loss
of the two good leaving imidazole groups on the CDI during ring closure is a possible
mechanistic explanation for this synthesis. Compound 8 was unambiguously confirmed by single
crystal X-ray analysis.24-27 Treatment of Compound 7 with thiocarbonyldiimidazole (TDI) in
dioxane under reflux afforded Compound 9 and upon further purification by flash gel column
chromatography resulted in yellow pure solid of 9. Recrystallization from methanol afforded
yellow crystals in 80% yield. Unlike the carbonylation of 7, the thionylation of 7 with TDI
resulted in the formation of a thiol compound instead of a thionyl compound. The delocalization
of electrons onto the large-sized sulphur atom aided the transfer of proton from the nitrogen atom
to the sulphur to form the thiol product.
A slight modification of the protocol used in Rekowski et al. and Bartsch et al.28,29 for
the synthesis optimization of Compound 10 was employed. Compound 2 was treated with
hydroxylamine hydrochloride under basic conditions. The use of K2CO3 as a relatively milder
base in place of triethylamine increased the % yield significantly to 94% as compared to 74%
reported in the literature.29 One possible explanation for this observation could be the ability of
the K2CO3 to effectively neutralize the HCl making the hydroxylamine a very good nucleophile
and readily available to attack the electrophilic thionyl carbon in 2. Recrystallization from
nitromethane afforded Compound 10 as yellow needle-like crystals.
Compound 10 was further used as the main precursor for the synthesis of oxadiazole (11)
and thionyl oxadiazole (12) by respective carbonylation and thiocarbonylation reactions which
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have been reported in literature.28,29 A slight modification was made to the reported protocol to
optimize the synthesis of 11 and 12 by treating 10 with carbonyldiimidazole and
thiocarbonyldiimidazole under reflux in dioxane for 12 hours to afford 11 and 12 in 88% and
90% yield, respectively. According to the literature, both reactions under reflux in THF take 24
hours to form their respective products in 84% yields.
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Scheme 3: Reagents and conditions: Reagents and conditions: (a) DMF, 155 °C, 5h, 82.0%; (b)
Lawesson’s reagent, THF, rt, 15h, 87.0%; (c) n-propylamine, HgCl2, rx, 1h, 88%; (d) bis(2,4,6trichlorophenyl)-2-phenylmalonate, 190 oC, 10 min, 75%; (e) NH3(g)(anhy.), HgCl2, THF, rx,
1h, 88% (f) bis(2,4,6-trichlorophenyl)-2-phenylmalonate, 210-220 oC, 10 min, 63%; (g)
N2H4.H2O(98%), EtOH(abs.), rt, 15h, 99.0%; (h) CDI, dioxane (anhy.), reflux, 24h, 99.0%; (i)
TDI, dioxane (anhy.), rx, 24h, 80.0%; (j) NH2OH.HCl, K2CO3, ethanol, rt, 24h, 82%; (k) CDI,
dioxane, rx, 12h, 88% / TDI, dioxane, rx, 12h, 90%; (l) α-bromoacetyl chloride, THF, rt, under
N2(g), 15h, 75%.
CDI: 1,1’-carbonyldiimidazole, TDI: 1,1’-thiocarbonyldiimidazole

X-ray Structural Analysis
Slow evaporation of a saturated solution of Compound 8 in ethyl acetate/hexane (4:1 v/v)
afforded colorless single crystals with an orthorhombic unit cell. The ORTEP molecular
structure and the crystallographic numbering are shown in Figure 8. The crystal strucutre in the
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elemental cell features intermolecular hydrogen bonds to the three units of molecules at
H3A···C1=O1, H3B···C10=O2, and O3···N4‒H4A, respectively. A twisted helical
conformation of the molecular structure can be visualized directly from the 6:7:5
pyrrolobenzodiazepine ring system while the 7-membered ring adopting a boat arrangement.
This finding is in agreement with the dihedral angles of N(2)-C(8)-C(9)-N(1) and N(1)-C(1)C(2)-C(7) which were determined to be 58.5(2)o and 38.6(2)o, respectively. The boat
conformation was further confirmed by the torsion angles of -6.0(2)o for C(9)-N(1)-C(1)-C(2)
and -2.5(2)o for C(1)-C(2)-C(7)-N(2). The bond distance of C(8)-N(3) was determined to be
128.8 pm and corresponds to the imino C(sp2)=N(sp2) double bond. In addition, the bond length
N(2)-C(8) was measured to be a single bond with a distance of 136.9 pm which confirms the
construction of 1,2,4-triazol-3(4H)-one annulated moiety. It’s interesting to note that the
presence of a distinct C(8)-C(9) single bond with a distance of 149.96 pm, unambiguously
excludes any tautomerization and verifies its parent S-configuration at carbon C11a which gives
the molecules a right-handed twist to interact with DNA double helix.

Figure 8: ORTEP projection of the X-ray crystal structure and Packing diagram of Compound 8.
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Biological Activity
MTT Cell Viability Test
To determine whether our PBD compounds were cytotoxic towards cancer cells, the
MTT assay was initially used for selected cell lines. The MTT assay is a colorimetric assay that
uses 3-(4,5-Dimethylthiazol-2-Yl)-2,5-diphenyltetrazolium bromide (MTT) to assess cell
metabolic activity. Based on the previously reported works, the preferred cancer cell lines that
were used for the MTT assay were breast (SK-BR-3, MCF-7), colon (CaCo-2, HCT 116),
melanoma (SKMEL-2), and pancreatic (Mia Paca) cell lines. The PBD compounds were dosed at
100 µM, and allowed to incubate for 48 hours. The optical densities of the crystals were then
measured at 590 nm using a BioTek Synergy HT spectrophotometer.
The results show that nearly all of the novel PBD compounds, except for Compound 13,
reduced the cell viability of MCF-7 cells by roughly up to 27% (Figure 9). In contrast, virtually
none of the PBD analogs, with the exception of Compounds 1 and 10, had an anti-proliferative
effect on the SKMEL-2 cell line. Additionally, all compounds that were tested on HCT-116 and
Mia Paca showed no cytotoxic effects. Compound 1 showed a decrease in cell viability for the
SKBR-3, MCF-7, SKMEL-2, and CaCo 2 cell lines; however, the PBD dilactam showed no
cytotoxicity towards HCT 116 or Mia Paca. The greatest amount of cytotoxicity for 1 was a
reduction of cell viability by 20.3% and 20.1% for both MCF-7 and SKMEL-2 cell lines,
respectively. Compound 2 showed a clear reduction of cell viability for MCF-7 and CaCo 2,
while having the greatest amount of anti-proliferative effects on the MCF-7 cell line (17.7%).
However, 2 did not noticeably decrease the cell viability of cell lines SKBR-3, SKMEL-2, HCT
116, or Mia Paca. Compound 3 had a relatively low effect on the cell viabilities of MCF-7
(10.4%) and CaCo 2 (7.5%) cells, while had no negative effect on the cell growth of SKBR-3,
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Mia Paca, SKMEL 2, and HCT 116 cell lines. Compound 4 had a noticeable effect on the cell
viabilities of SKBR-3 (17.3%) and MCF-7 (22.5%). However, 4 had no negative effects on the
cell growth of SKMEL-2, CaCo 2, HCT 116, or Mia Paca cell lines. Compound 5 showed the
highest growth inhibition against MCF-7 cell line (26.4%) when compared with other tested
analogs. 5 had no negative effect on the cell viability of SKBR-3, SKMEL-2, and CaCo 2.
Compounds 6 and 8 displayed some reduction in the cell viability of SKMEL-2 with values of
19.9% and 17.0%, respectively. Compounds 10 and 11 showed their highest inhibition activity
versus SKMEL-2 breast cell line with 13.0% and 10.5%, respectively. Compound 13 had a
selective anti-proliferative effect on CaCo 2 cell line (13.6%).
In vitro Cytotoxicity
In order to validate our preliminary in-house MTT cell viability results and further
expand the number of cancer cell lines, nine PBD analogs were selected for the single-dose in
vitro cytotoxicity using a panel of NCI-60 cell lines as part of Developmental Therapeutics
Program (DTP) at the National Cancer Institute. Similar results were obtained in agreement with
the MTT data (Table 1). All the compounds were shown to have some non-selective growth
inhibition on T-47D breast cell line ranging from 6.7 to 12.7%. Interestingly, Compounds 3 and
4 displayed their highest inhibition on SNB-75 (CNS) (12.3%) and NCI-H522 (NSCL) (12.2%),
respectively. The best inhibition activity was exhibited by 6 which exclusively acts on the renal
UO-31 cell line with 28.5% growth inhibition.
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Figure 9: In vitro cytotoxicity assay of PBD analogues using the MTT Assay.

Cancer

Cell line

Leukemia

HL-60(TB)
SR
HOP-62
NCI-H522
HCT-116
HT29
SNB-75
U251
SKMEL-2
MALME-3M
NCI/ADR-RES
SK-OV-3
UO-31
TK-10
PC-3
T-47D
HS 578T

NSCL
Colon
CNS
Melanoma
Ovarian
Renal
Prostate
Breast

PBD Compounds-Growth Percent
8
10
11

3

4

5

6

101.38
102.79
101.62
84.29
100.33
97.57
77.68
98.25
95.73
92.15
97.24
103.74
85.88
92.55
98.28
88.30
94.34

103.22
103.91
89.44
77.82
96.01
99.46
87.15
99.23
91.26
95.68
95.76
98.55
83.90
94.15
95.79
88.54
98.16

103.05
95.32
84.60
83.64
96.12
101.60
83.05
91.64
96.42
97.19
102.94
95.20
78.66
94.62
89.08
89.48
92.43

101.26
103.31
90.25
78.63
99.44
95.26
84.45
98.40
96.80
94.85
95.62
106.55
71.55
90.33
90.37
91.74
94.98

101.25
92.26
77.32
76.35
98.34
98.65
88.78
95.70
90.48
88.95
104.82
88.06
89.20
96.45
95.76
83.60
96.69

90.92
99.34
91.39
79.92
98.34
94.64
93.52
96.42
91.71
95.21
100.80
101.62
86.24
92.33
95.37
92.91
99.98

103
103.8
80.34
90.49
101.09
95.04
89.29
96.22
97.71
83.85
99.31
88.46
88.38
95.19
97.71
93.26
98.31

12

13

94.58
91.96
92.91
76.82
95.49
99.63
90.43
95.79
82.08
98.70
104.39
92.95
87.04
96.05
90.70
91.42
96.79

87.83
101.39
87.54
81.50
88.64
91.31
85.08
96.22
94.75
100.22
100.73
90.84
80.50
98.39
88.45
87.23
94.58

Table 1: In vitro cytotoxicity data of PBD derivatives against a number of NCI-60 cell lines.
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CONCLUSIONS
In conclusion, PBD dilactam (1) (formed from the cyclocondensation of commercially
available isatoic anhydride with L-proline in DMF for 5 hours) was synthesized and used as the
core structure for all of the PBD analogous in this project. Compound 2, which was synthesized
via the thionation of dilactam 1, was used as the starting material for the syntheses of PBDs 3-13.
In order to test the anti-proliferative activity of the PBD products, the MTT assay was first
implemented. For the MTT assay, the PBD products were the most effective against the MCF-7;
all of the PBDs, except for Compound 13, reduced the cell viability of MCF-7 cells to roughly
27%. In contrast to MCF-7, virtually none of the PBD analogs, with the exception of compounds
1 and 10, had an anti-proliferative effect on the SKMEL-2 cell line. Additionally, all compounds
that were tested on HCT-116 and Mia Paca showed no cytotoxic effects.
In order to verify our preliminary in-house MTT cell viability results, and to further
expand the number of cancer cell lines used to test the PBD compounds, nine PBD analogs were
selected for the single-dose in vitro cytotoxicity using a panel of NCI-60 cell lines as part of
Developmental Therapeutics Program (DTP) at the National Cancer Institu4te. The PBDs
produced similar results in the NCI-60 cell lines as compared to the cell lines used for the MTT
Assay. The best anti-proliferative activity against the NCI-60 cell lines was exhibited by PBD 6
which exclusively acts on the renal UO-31 cell line with 28.5% growth inhibition.
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FUTURE WORK
In order to increase cytotoxicity, unsaturation of the PBDs at the C2 position of the core
structure may be included in future projects. Additionally, tetracyclic PBDs may have steric
hindrance when entering the minor groove, which would prevent the alkylation of DNA;
successful compounds such as anthramycin could be modified to contain a tetracyclic structure
in order to determine whether steric hindrance should be considered.
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APPENDICES
Appendix A1: 1H-NMR Spectrum for Compound 1 in DMSO-d6
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Appendix A2: 1H-NMR Spectrum for Compound 1 in DMSO-d6
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Appendix A3: 1H-NMR Spectrum for Compound 1 in DMSO-d6
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Appendix A4: 13C-NMR Spectrum for Compound 1 in DMSO-d6
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Appendix A5: C DEPT-135 NMR Spectrum for Compound 1 in DMSO-d6
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Appendix A6: GC-MS Spectrum for Compound 1
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Appendix A7: IR Spectrum for Compound 1
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